3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Myeloid Malignancies
1
Multiple Myeloma
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Colorectal Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cyclophosphamide
34
Busulfan
32
fludarabine phosphate
29
Cyclosporine
24
Mycophenolic Acid
22
Peripheral Blood Stem Cell Transplantation
21
Whole-Body Irradiation
19
Antilymphocyte Serum
19
Tacrolimus
15
Methotrexate
15
Cytarabine
15
fludarabine
14
Melphalan
14
Cord Blood Stem Cell Transplantation
14
Radiotherapy
13
Filgrastim
12
Methylprednisolone
9
Granulocyte Colony-Stimulating Factor
9
Etoposide
7
Thiotepa
6
thymoglobulin
5
sargramostim
5
Idarubicin
5
Cyclosporins
5
Clofarabine
5
Azacitidine
5
merphos
4
Gemtuzumab
4
Decitabine
4
Arsenic Trioxide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Anemia, Refractory, with Excess of Blasts
×
magrolimab
×
Clear all
NCT05829434
2024-02-12
MAGROLIC
University of Leipzig
Phase 2
Withdrawn